{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:22:49Z","timestamp":1769170969457,"version":"3.49.0"},"publisher-location":"Cham","reference-count":139,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319720760","type":"print"},{"value":"9783319720777","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-72077-7_9","type":"book-chapter","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T23:05:04Z","timestamp":1525388704000},"page":"173-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic Antibodies for Biodefense"],"prefix":"10.1007","author":[{"given":"Arnaud","family":"Avril","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,17]]},"reference":[{"key":"9_CR1","unstructured":"United Nations Office For Disarmament Affaires: Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction. https:\/\/www.un.org\/disarmament\/wmd\/bio\/"},{"key":"9_CR2","unstructured":"Anderson F (2007) Crucible of war: the seven years\u2019 war and the fate of empire in British North America, 1754\u20131766. Knopf Doubleday Publishing Group, New York"},{"key":"9_CR3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1586\/14787210.2014.945917","volume":"12","author":"F Anniballi","year":"2014","unstructured":"Anniballi F, Lonati D, Fiore A, Auricchio B, De Medici D, Locatelli CA (2014) New targets in the search for preventive and therapeutic agents for botulism. Expert Rev Anti-Infect Ther 12:1075\u20131086","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"9_CR4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","volume":"285","author":"SS Arnon","year":"2001","unstructured":"Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059\u20131070","journal-title":"JAMA"},{"key":"9_CR5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1056\/NEJMoa051926","volume":"354","author":"SS Arnon","year":"2006","unstructured":"Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL (2006) Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354:462\u2013471","journal-title":"N Engl J Med"},{"key":"9_CR6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jim.2007.06.003","volume":"325","author":"O Attr\u00e9e","year":"2007","unstructured":"Attr\u00e9e O, Guglielmo-Viret V, Gros V, Thullier P (2007) Development and comparison of two immunoassay formats for rapid detection of botulinum neurotoxin type A. J Immunol Methods 325:78\u201387","journal-title":"J Immunol Methods"},{"key":"9_CR7","unstructured":"The Australia Group (website). http:\/\/www.australiagroup.net\/fr"},{"key":"9_CR8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12896-015-0206-0","volume":"15","author":"A Avril","year":"2015","unstructured":"Avril A, Miethe S, Popoff MR, Mazuet C, Chahboun S, Rasetti-Escargueil C, Sesardic D, Thullier P, Hust M, Pelat T (2015) Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A 1 and A 2 by targeting their heavy chain. BMC Biotechnol 15:86","journal-title":"BMC Biotechnol"},{"key":"9_CR9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/15701638113109990030","volume":"11","author":"A Avril","year":"2014","unstructured":"Avril A, Froude JW, Mathieu J, Pelat T, Thullier P (2014) Isolation of antibodies from non-human primates for clinical use. Curr Drug Discov Technol 11:20\u201327","journal-title":"Curr Drug Discov Technol"},{"key":"9_CR10","unstructured":"Ballard T, Pate J, Ackerman G, McCauley D, Lawson S (2001) Chronology of Aum Shinrikyo\u2019s CBW activities. Monterey Institute of International Studies, Center for Nonproliferation Studies"},{"key":"9_CR11","unstructured":"Barenblatt D (2004) A plague upon humanity: the secret genocide of axis Japan\u2019s germ warfare operation"},{"key":"9_CR12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/1469-0691.12706","volume":"20","author":"V Barras","year":"2014","unstructured":"Barras V, Greub G (2014) History of biological warfare and bioterrorism. Clin Microbiol Infect 20:497\u2013502","journal-title":"Clin Microbiol Infect"},{"key":"9_CR13","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/JVI.02152-12","volume":"87","author":"MR-E-I Benhnia","year":"2013","unstructured":"Benhnia MR-E-I, Maybeno M, Blum D, Aguilar-Sino R, Matho M, Meng X, Head S, Felgner PL, Zajonc DM, Koriazova L (2013) Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. J Virol 87:1569\u20131585","journal-title":"J Virol"},{"key":"9_CR14","first-page":"206","volume":"22","author":"P Berche","year":"2006","unstructured":"Berche P (2006) Scientific progress and new biological weapons. Med Sci 22:206\u2013211","journal-title":"Med Sci"},{"key":"9_CR15","unstructured":"Berche P (2009) L\u2019histoire des guerres biologiques secr\u00e8tes: mensonges et crimes d\u2019\u00e9tat. In: Montr\u00e9al, QC, Canada: University of Montr\u00e9al conference"},{"key":"9_CR16","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1128\/AAC.00208-15","volume":"59","author":"A Berhanu","year":"2015","unstructured":"Berhanu A, Prigge JT, Silvera PM, Honeychurch KM, Hruby DE, Grosenbach DW (2015) Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection. Antimicrob Agents Chemother 59:4296\u20134300","journal-title":"Antimicrob Agents Chemother"},{"key":"9_CR17","doi-asserted-by":"crossref","unstructured":"Boisset S, Caspar Y, Sutera V, Maurin M (2014) New therapeutic approaches for treatment of tularaemia: a review. Front Cell Infect Microbiol 4:\u201340","DOI":"10.3389\/fcimb.2014.00040"},{"key":"9_CR18","first-page":"1","volume":"64","author":"WA Bower","year":"2015","unstructured":"Bower WA, Hendricks K, Pillai S, Guarnizo J, Meaney-Delman D, Centers for Disease Control and Prevention (2015) Clinical framework and medical countermeasure use during an anthrax mass-casualty incident\u2014CDC recommendations. MMWR Morb Mortal Wkly Rep 64:1\u201321","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"9_CR19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003455","volume":"9","author":"C Br\u00e9zillon","year":"2015","unstructured":"Br\u00e9zillon C, Haustant M, Dupke S, Corre J-P, Lander A, Franz T, Monot M, Couture-Tosi E, Jouvion G, Leendertz FH (2015) Capsules, toxins and AtxA as virulence factors of emerging Bacillus cereus biovar anthracis. PLoS Negl Trop Dis 9:e0003455","journal-title":"PLoS Negl Trop Dis"},{"key":"9_CR20","unstructured":"Buisson Y, Cavallo J-D, Kowalski J-J, Tr\u00e9guier J-Y (2004) Les risques NRBC, savoir pour agir. Xavier Montauban SA"},{"key":"9_CR21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.coph.2016.08.016","volume":"30","author":"AP Cardile","year":"2016","unstructured":"Cardile AP, Downey LG, Wiseman PD, Warren TK, Bavari S (2016) Antiviral therapeutics for the treatment of Ebola virus infection. Curr Opin Pharmacol 30:138\u2013143","journal-title":"Curr Opin Pharmacol"},{"key":"9_CR22","unstructured":"Classification of biological agents according to the Centers for Diseases Control and Prevention. http:\/\/www.bt.cdc.gov\/agent\/agentlistcategory.asp"},{"key":"9_CR23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/1471-2334-14-234","volume":"14","author":"V Chaignat","year":"2014","unstructured":"Chaignat V, Djordjevic-Spasic M, Ruettger A, Otto P, Klimpel D, M\u00fcller W, Sachse K, Araj G, Diller R, Tomaso H (2014) Performance of seven serological assays for diagnosing tularemia. BMC Infect Dis 14:234","journal-title":"BMC Infect Dis"},{"key":"9_CR24","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1128\/JVI.00906-07","volume":"81","author":"Z Chen","year":"2007","unstructured":"Chen Z, Earl P, Americo J, Damon I, Smith SK, Yu F, Sebrell A, Emerson S, Cohen G, Eisenberg RJ (2007) Characterization of chimpanzee\/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol 81:8989\u20138995","journal-title":"J Virol"},{"key":"9_CR25","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1073\/pnas.0510598103","volume":"103","author":"Z Chen","year":"2006","unstructured":"Chen Z, Earl P, Americo J, Damon I, Smith SK, Zhou Y-H, Yu F, Sebrell A, Emerson S, Cohen G (2006) Chimpanzee\/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A 103:1882\u20131887","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR26","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1080\/21645515.2016.1175261","volume":"12","author":"K Chu","year":"2016","unstructured":"Chu K, Hu J, Meng F, Li J, Luo L, Xu J, Yuan Z, Li Z, Chen W, Jiao L (2016) Immunogenicity and safety of subunit plague vaccine: a randomized phase 2a clinical trial. Hum Vaccin Immunother 12:2334\u20132340","journal-title":"Hum Vaccin Immunother"},{"key":"9_CR27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1126\/science.351.6268.12","volume":"351","author":"J Cohen","year":"2016","unstructured":"Cohen J, Enserink M (2016) As Ebola epidemic draws to a close, a thin scientific harvest. Science 351:12\u201313","journal-title":"Science"},{"key":"9_CR28","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1016\/j.molimm.2008.01.022","volume":"45","author":"JW Conlan","year":"2008","unstructured":"Conlan JW, Zhao X, Harris G, Shen H, Bolanowski M, Rietz C, Sjostedt A, Chen W (2008) Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis. Mol Immunol 45:2962\u20132969","journal-title":"Mol Immunol"},{"key":"9_CR29","first-page":"299","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","unstructured":"Centers for Disease Control and Prevention (2010) Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep 59:299","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"9_CR30","volume-title":"Weapons of mass destruction: an encyclopedia of worldwide policy, technology, and history","author":"EA Croddy","year":"2005","unstructured":"Croddy EA, Wirtz JJ (2005) Weapons of mass destruction: an encyclopedia of worldwide policy, technology, and history, vol 2. ABC-CLIO I, Santa Barbara"},{"key":"9_CR31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/bsp.2011.0104","volume":"10","author":"R Danzig","year":"2012","unstructured":"Danzig R (2012) A decade of countering bioterrorism: incremental progress, fundamental failings. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 10:49\u201354","journal-title":"Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science"},{"key":"9_CR32","unstructured":"Dembek ZF (2016) USAMRIID\u2019s medical management of biological casualties handbook. Government Printing Office"},{"key":"9_CR33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/toxins8090257","volume":"8","author":"Y Derman","year":"2016","unstructured":"Derman Y, Selby K, Miethe S, Frenzel A, Liu Y, Rasetti-Escargueil C, Avril A, Pelat T, Urbain R, Fontayne A (2016) Neutralization of botulinum neurotoxin type E by a humanized antibody. Toxins 8:257","journal-title":"Toxins"},{"key":"9_CR34","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","volume":"11","author":"Y Edghill-Smith","year":"2005","unstructured":"Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, Nalca A, Hooper JW, Whitehouse CA, Schmitz JE (2005) Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11:740","journal-title":"Nat Med"},{"key":"9_CR35","first-page":"637","volume":"73","author":"RH Egdahl","year":"1973","unstructured":"Egdahl RH (1973) Ambulatory health-care delivery and the surgeon. Surgery 73:637\u2013638","journal-title":"Surgery"},{"key":"9_CR36","unstructured":"FDA (2007) Transcripts of workshop, Anthrax: bridging correlates of protection in animals to immunogenicity in humans"},{"key":"9_CR37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/imr.12363","volume":"268","author":"S Foss","year":"2015","unstructured":"Foss S, Watkinson R, Sandlie I, James LC, Andersen JT (2015) TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity. Immunol Rev 268:328\u2013339","journal-title":"Immunol Rev"},{"key":"9_CR38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","volume":"37","author":"VA Fulginiti","year":"2003","unstructured":"Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson D, Henderson DA, Inglesby TV Jr, O\u2019Toole T (2003) Smallpox vaccination: a review, Part II. Adverse events. Clin Infect Dis 37:251\u2013271","journal-title":"Clin Infect Dis"},{"key":"9_CR39","volume":"6","author":"W Furuyama","year":"2016","unstructured":"Furuyama W, Marzi A, Nanbo A, Haddock E, Maruyama J, Miyamoto H, Igarashi M, Yoshida R, Noyori O, Feldmann H (2016) Discovery of an antibody for pan-ebolavirus therapy. Sci Rep 6:20514","journal-title":"Sci Rep"},{"key":"9_CR40","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cell.2016.09.049","volume":"167","author":"I Gilchuk","year":"2016","unstructured":"Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, Blum DL, Hughes LJ, Satheshkumar PS, Townsend MB (2016) Cross-neutralizing and protective human antibody specificities to poxvirus infections. Cell 167:684\u2013694.e689","journal-title":"Cell"},{"key":"9_CR41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/MMBR.46.1.86-94.1982","volume":"46","author":"DM Gill","year":"1982","unstructured":"Gill DM (1982) Bacterial toxins: a table of lethal amounts. Microbiol Rev 46:86","journal-title":"Microbiol Rev"},{"key":"9_CR42","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/bmj.291.6494.530","volume":"291","author":"RH Girdwood","year":"1985","unstructured":"Girdwood RH (1985) Experimentation on prisoners by the Japanese during World War II. Br Med J (Clin Res Ed) 291:530\u2013531","journal-title":"Br Med J (Clin Res Ed)"},{"key":"9_CR43","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fvl.11.27","volume":"6","author":"DW Grosenbach","year":"2011","unstructured":"Grosenbach DW, Jordan R, Hruby DE (2011) Development of the small-molecule antiviral ST-246\u00ae as a smallpox therapeutic. Futur Virol 6:653\u2013671","journal-title":"Futur Virol"},{"key":"9_CR44","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/15563650701354226","volume":"45","author":"V Guglielmo-Viret","year":"2007","unstructured":"Guglielmo-Viret V, Splettstoesser W, Thullier P (2007) An immunochromatographic test for the diagnosis of ricin inhalational poisoning. Clin Toxicol 45:505\u2013511","journal-title":"Clin Toxicol"},{"key":"9_CR45","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1017\/dmp.2016.39","volume":"10","author":"TA Hadi","year":"2016","unstructured":"Hadi TA, Fleshler K (2016) Integrating social media monitoring into public health emergency response operations. Disaster Med Public Health Prep 10:775\u2013780","journal-title":"Disaster Med Public Health Prep"},{"key":"9_CR46","unstructured":"Louisiana Office of Public Health (2013) Botulism \u2013 annual report. Retrieved on 01\/01\/2018 from http:\/\/new.dhh.louisiana.gov\/assets\/oph\/Center-PHCH\/Center-CH\/infectious-epi\/Annuals\/Botulism_LaIDAnnual.pdf"},{"key":"9_CR47","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1126\/science.283.5406.1279","volume":"283","author":"DA Henderson","year":"1999","unstructured":"Henderson DA (1999) The looming threat of bioterrorism. Science 283:1279\u20131282","journal-title":"Science"},{"key":"9_CR48","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1128\/IAI.71.4.2234-2238.2003","volume":"71","author":"J Hill","year":"2003","unstructured":"Hill J, Copse C, Leary S, Stagg AJ, Williamson ED, Titball RW (2003) Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun 71:2234\u20132238","journal-title":"Infect Immun"},{"key":"9_CR49","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1128\/JB.01180-06","volume":"189","author":"K Hill","year":"2007","unstructured":"Hill K, Smith T, Helma C, Ticknor L, Foley B, Svensson R, Brown J, Johnson E, Smith L, Okinaka R (2007) Genetic diversity among botulinum neurotoxin-producing clostridial strains. J Bacteriol 189:818\u2013832","journal-title":"J Bacteriol"},{"key":"9_CR50","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1345\/aph.1R646","volume":"47","author":"SE Hill","year":"2013","unstructured":"Hill SE, Iqbal R, Cadiz CL, Le J (2013) Foodborne botulism treated with heptavalent botulism antitoxin. Ann Pharmacother 47:e12\u2013e12","journal-title":"Ann Pharmacother"},{"key":"9_CR51","doi-asserted-by":"crossref","unstructured":"Hobbs C, Myles P, Pritchard C (2016) A content analysis of the UK press response to the diagnosis of Ebola in a British healthcare worker. J Public Health 1\u201310","DOI":"10.1093\/pubmed\/fdw105"},{"key":"9_CR52","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/0003-4819-144-4-200602210-00009","volume":"144","author":"J-EC Holty","year":"2006","unstructured":"Holty J-EC, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK (2006) Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 144:270\u2013280","journal-title":"Ann Intern Med"},{"key":"9_CR53","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1128\/CVI.00013-14","volume":"21","author":"MI Ivanov","year":"2014","unstructured":"Ivanov MI, Hill J, Bliska JB (2014) Direct neutralization of type III effector translocation by the variable region of a monoclonal antibody to Yersinia pestis LcrV. Clin Vaccine Immunol 21:667\u2013673","journal-title":"Clin Vaccine Immunol"},{"key":"9_CR54","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3201\/eid0810.020353","volume":"8","author":"DB Jernigan","year":"2002","unstructured":"Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, Cetron M, Cohen M, Doyle T, Fischer M (2002) Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 8:1019","journal-title":"Emerg Infect Dis"},{"key":"9_CR55","unstructured":"Reid K (2005) Using the flea as weapon. Army Chem Rev"},{"key":"9_CR56","doi-asserted-by":"crossref","first-page":"11339","DOI":"10.1128\/JVI.01491-14","volume":"88","author":"T Kaever","year":"2014","unstructured":"Kaever T, Meng X, Matho MH, Schlossman A, Li S, Sela-Culang I, Ofran Y, Buller M, Crump RW, Parker S (2014) Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein. J Virol 88:11339\u201311355","journal-title":"J Virol"},{"key":"9_CR57","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1128\/JCM.39.12.4566-4567.2001","volume":"39","author":"P Keim","year":"2001","unstructured":"Keim P, Smith KL, Keys C, Takahashi H, Kurata T, Kaufmann A (2001) Molecular investigation of the Aum Shinrikyo anthrax release in Kameido, Japan. J Clin Microbiol 39:4566\u20134567","journal-title":"J Clin Microbiol"},{"key":"9_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diagmicrobio.2012.05.030","volume":"74","author":"S K\u0131l\u0131\u00e7","year":"2012","unstructured":"K\u0131l\u0131\u00e7 S, \u00c7elebi B, Ye\u015filyurt M (2012) Evaluation of a commercial immunochromatographic assay for the serologic diagnosis of tularemia. Diagn Microbiol Infect Dis 74:1\u20135","journal-title":"Diagn Microbiol Infect Dis"},{"key":"9_CR59","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4049\/jimmunol.179.1.532","volume":"179","author":"GS Kirimanjeswara","year":"2007","unstructured":"Kirimanjeswara GS, Golden JM, Bakshi CS, Metzger DW (2007) Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 179:532\u2013539","journal-title":"J Immunol"},{"key":"9_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/157895","volume":"2014","author":"P Klasse","year":"2014","unstructured":"Klasse P (2014) Neutralization of virus infectivity by antibodies: old problems in new perspectives. Adv Biol 2014:1\u201324","journal-title":"Adv Biol"},{"key":"9_CR61","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1006\/jmbi.1999.2945","volume":"291","author":"DB Lacy","year":"1999","unstructured":"Lacy DB, Stevens RC (1999) Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 291:1091\u20131104","journal-title":"J Mol Biol"},{"key":"9_CR62","unstructured":"Lang P (2003) Rapport D\u2019information N\u00b01097 de L\u2019assembl\u00e9e Nationale Sur Le Bioterrorisme. President of the National Assembly. Available via The Committee on National Defense and Armed Forces. http:\/\/www.assemblee-nationale.fr\/12\/rap-info\/i1097.asp"},{"key":"9_CR63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-61779-974-7_1","volume":"907","author":"M-P Lefranc","year":"2012","unstructured":"Lefranc M-P, Ehrenmann F, Ginestoux C, Giudicelli V, Duroux P (2012) Use of IMGT\u00ae databases and tools for antibody engineering and humanization. Methods Mol Biol 907:3\u201337","journal-title":"Methods Mol Biol"},{"key":"9_CR64","unstructured":"L\u00e9gifrance (2008) Labor code\u00a0\u2013 article R4421-2. Available via French Legal System. http:\/\/www.legifrance.gouv.fr\/affichCodeArticle.do?idArticle=LEGIARTI000018530510&cidTexte=LEGITEXT000006072050&dateTexte=20100316&oldAction=rechCodeArticle"},{"key":"9_CR65","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.vaccine.2010.08.099","volume":"29","author":"J-S Lin","year":"2010","unstructured":"Lin J-S, Park S, Adamovicz JJ, Hill J, Bliska JB, Cote CK, Perlin DS, Amemiya K, Smiley ST (2010) TNF\u03b1 and IFN\u03b3 contribute to F1\/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine 29:357\u2013362","journal-title":"Vaccine"},{"key":"9_CR66","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/imm.12150","volume":"140","author":"Z Lu","year":"2013","unstructured":"Lu Z, Rynkiewicz MJ, Yang CY, Madico G, Perkins HM, Wang Q, Costello CE, Zaia J, Seaton BA, Sharon J (2013) The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide. Immunology 140:374\u2013389","journal-title":"Immunology"},{"key":"9_CR67","unstructured":"M M (1999) Rapport De La Sous-Commission Sur La Prolif\u00e9ration Des Technologies Militaires. \u2018Technologie Et Terrorisme\u2019. l\u2019Assembl\u00e9e Parlementaire de l\u2019OTAN"},{"key":"9_CR68","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/oxfordjournals.aje.a121380","volume":"95","author":"TM Mack","year":"1972","unstructured":"Mack TM, Thomas DB, Ali A, Khan MM (1972) Epidemiology of smallpox in West Pakistan: I. Acquired immunity and the distribution of disease. Am J Epidemiol 95:157\u2013168","journal-title":"Am J Epidemiol"},{"key":"9_CR69","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/AAC.02295-13","volume":"58","author":"NV Malkevich","year":"2014","unstructured":"Malkevich NV, Hopkins RJ, Bernton E, Meister GT, Vela EM, Atiee G, Johnson V, Nabors GS, Aimes RT, Ionin B (2014) Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans. Antimicrob Agents Chemother 58:3618\u20133625","journal-title":"Antimicrob Agents Chemother"},{"key":"9_CR70","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.csbj.2016.07.003","volume":"14","author":"AL Marschall","year":"2016","unstructured":"Marschall AL, D\u00fcbel S (2016) Antibodies inside of a cell can change its outside: can intrabodies provide a new therapeutic paradigm? Comput Struct Biotechnol J 14:304\u2013308","journal-title":"Comput Struct Biotechnol J"},{"key":"9_CR71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005148","volume":"11","author":"MH Matho","year":"2015","unstructured":"Matho MH, Schlossman A, Meng X, Benhnia MR-E-I, Kaever T, Buller M, Doronin K, Parker S, Peters B, Crotty S (2015) Structural and functional characterization of anti-a33 antibodies reveal a potent cross-species orthopoxviruses neutralizer. PLoS Pathog 11:e1005148","journal-title":"PLoS Pathog"},{"key":"9_CR72","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3851\/IMP1573","volume":"15","author":"MM McCausland","year":"2010","unstructured":"McCausland MM, Benhnia MR-E-I, Crickard L, Laudenslager J, Granger SW, Tahara T, Kubo R, Koriazova L, Kato S, Crotty S (2010) Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir Ther 15:661","journal-title":"Antivir Ther"},{"key":"9_CR73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ni.2548","volume":"14","author":"WA McEwan","year":"2013","unstructured":"McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC (2013) Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 14:327\u2013336","journal-title":"Nat Immunol"},{"key":"9_CR74","unstructured":"meeting Varbpac (2010) Pathway to licensure for protective antigen-based anthrax vaccines for a post-exposure prophylaxis indication using the animal rule"},{"key":"9_CR75","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1126\/science.7973702","volume":"266","author":"M Meselson","year":"1994","unstructured":"Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O (1994) The Sverdlovsk anthrax outbreak of 1979. Science 266:1202\u20131208","journal-title":"Science"},{"key":"9_CR76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161446","volume":"11","author":"S Miethe","year":"2016","unstructured":"Miethe S, Mazuet C, Liu Y, Tierney R, Rasetti-Escargueil C, Avril A, Frenzel A, Thullier P, Pelat T, Urbain R (2016) Development of germline-humanized antibodies neutralizing botulinum neurotoxin A and B. PLoS One 11:e0161446","journal-title":"PLoS One"},{"key":"9_CR77","doi-asserted-by":"crossref","unstructured":"Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, Frenzel A, Schirrmann T, Thullier P, Sesardic D (2014) Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. In: MAbs, vol 2. Taylor & Francis, pp 446\u2013459","DOI":"10.4161\/mabs.27773"},{"key":"9_CR78","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa0810603","volume":"361","author":"T-S Migone","year":"2009","unstructured":"Migone T-S, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A (2009) Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361:135\u2013144","journal-title":"N Engl J Med"},{"key":"9_CR79","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/milmed\/160.11.547","volume":"160","author":"JA Mobley","year":"1995","unstructured":"Mobley JA (1995) Biological warfare in the twentieth century: lessons from the past, challenges for the future. Mil Med 160:547\u2013553","journal-title":"Mil Med"},{"key":"9_CR80","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","volume":"239","author":"B Moss","year":"2011","unstructured":"Moss B (2011) Smallpox vaccines: targets of protective immunity. Immunol Rev 239:8\u201326","journal-title":"Immunol Rev"},{"key":"9_CR81","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1128\/AAC.00458-13","volume":"57","author":"N Mytle","year":"2013","unstructured":"Mytle N, Hopkins RJ, Malkevich NV, Basu S, Meister GT, Sanford DC, Comer JE, Van Zandt KE, Al-Ibrahim M, Kramer WG (2013) Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother 57:5684\u20135692","journal-title":"Antimicrob Agents Chemother"},{"key":"9_CR82","doi-asserted-by":"crossref","unstructured":"Nester WR (2000) \u201cHaughty conquerors\u201d: Amherst and the great Indian uprising of 1763. Greenwood Publishing Group","DOI":"10.5040\/9798400604980"},{"key":"9_CR83","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1365-2249.2008.03842.x","volume":"155","author":"M Okajima","year":"2009","unstructured":"Okajima M, Wada T, Nishida M, Yokoyama T, Nakayama Y, Hashida Y, Shibata F, Tone Y, Ishizaki A, Shimizu M, Saito T, Ohta K, Toma T, Yachie A (2009) Analysis of T cell receptor V\u03b2 diversity in peripheral CD4(+) and CD8(+) T lymphocytes in patients with autoimmune thyroid diseases. Clin Exp Immunol 155:166\u2013172. https:\/\/doi.org\/10.1111\/j.1365-2249.2008.03842.x","journal-title":"Clin Exp Immunol"},{"key":"9_CR84","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1128\/AAC.02814-14","volume":"58","author":"VA Olson","year":"2014","unstructured":"Olson VA, Smith SK, Foster S, Li Y, Lanier ER, Gates I, Trost LC, Damon IK (2014) In vitro efficacy of brincidofovir against variola virus. Antimicrob Agents Chemother 58:5570\u20135571","journal-title":"Antimicrob Agents Chemother"},{"key":"9_CR85","unstructured":"Organization WH (2007) WHO guidelines on tularaemia"},{"key":"9_CR86","unstructured":"Organization WH (2016) Clinical management of patients with viral haemorrhagic fever: a pocket guide for front-line health workers: interim emergency guidance for country adaptation"},{"key":"9_CR87","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.3923\/pjbs.2008.2370.2371","volume":"11","author":"M Papaloucas","year":"2008","unstructured":"Papaloucas M, Papaloucas C, Stergioulas A (2008) Ricin and the assassination of Georgi Markov. Pak J Biol Sci 11:2370\u20132371","journal-title":"Pak J Biol Sci"},{"key":"9_CR88","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tim.2015.11.008","volume":"24","author":"RD Pechous","year":"2016","unstructured":"Pechous RD, Sivaraman V, Stasulli NM, Goldman WE (2016) Pneumonic plague: the darker side of Yersinia pestis. Trends Microbiol 24:190\u2013197","journal-title":"Trends Microbiol"},{"key":"9_CR89","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jmb.2008.10.033","volume":"384","author":"T Pelat","year":"2008","unstructured":"Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc M-P, Thullier P (2008) Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 384:1400\u20131407","journal-title":"J Mol Biol"},{"key":"9_CR90","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1472-6750-9-60","volume":"9","author":"T Pelat","year":"2009","unstructured":"Pelat T, Hust M, Hale M, Lefranc M-P, D\u00fcbel S, Thullier P (2009) Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol 9:60","journal-title":"BMC Biotechnol"},{"key":"9_CR91","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1128\/IAI.00352-07","volume":"75","author":"JW Peterson","year":"2007","unstructured":"Peterson JW, Comer JE, Baze WB, Noffsinger DM, Wenglikowski A, Walberg KG, Hardcastle J, Pawlik J, Bush K, Taormina J (2007) Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun 75:3414\u20133424","journal-title":"Infect Immun"},{"key":"9_CR92","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/IAI.74.2.1016-1024.2006","volume":"74","author":"JW Peterson","year":"2006","unstructured":"Peterson JW, Comer JE, Noffsinger DM, Wenglikowski A, Walberg KG, Chatuev BM, Chopra AK, Stanberry LR, Kang AS, Scholz WW (2006) Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun 74:1016\u20131024","journal-title":"Infect Immun"},{"key":"9_CR93","doi-asserted-by":"crossref","first-page":"7299","DOI":"10.1016\/j.vaccine.2015.10.094","volume":"33","author":"PR Pittman","year":"2015","unstructured":"Pittman PR, Reisler RB, Lindsey CY, G\u00fcere\u00f1a F, Rivard R, Clizbe DP, Chambers M, Norris S, Smith LA (2015) Safety and immunogenicity of ricin vaccine, RVEc\u2122, in a Phase 1 clinical trial. Vaccine 33:7299\u20137306","journal-title":"Vaccine"},{"key":"9_CR94","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","volume":"375","author":"I Prevail","year":"2016","unstructured":"Prevail I, Team M-NPIS (2016) A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 375:1448","journal-title":"N Engl J Med"},{"key":"9_CR95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","volume":"514","author":"X Qiu","year":"2014","unstructured":"Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp\u2122. Nature 514:47","journal-title":"Nature"},{"key":"9_CR96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000421","volume":"3","author":"M Rajerison","year":"2009","unstructured":"Rajerison M, Dartevelle S, Ralafiarisoa LA, Bitam I, Tuyet DTN, Andrianaivoarimanana V, Nato F, Rahalison L (2009) Development and evaluation of two simple, rapid immunochromatographic tests for the detection of Yersinia pestis antibodies in humans and reservoirs. PLoS Negl Trop Dis 3:e421","journal-title":"PLoS Negl Trop Dis"},{"key":"9_CR97","doi-asserted-by":"crossref","unstructured":"Rasetti-Escargueil C, Avril A, Chahboun S, Tierney R, Bak N, Miethe S, Mazuet C, Popoff MR, Thullier P, Hust M (2015) Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B. In: MAbs, vol 6. Taylor & Francis, pp 1161\u20131177","DOI":"10.1080\/19420862.2015.1082016"},{"key":"9_CR98","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bios.2014.09.090","volume":"65","author":"T Read","year":"2015","unstructured":"Read T, Olkhov RV, Williamson ED, Shaw AM (2015) Kinetic epitope mapping of monoclonal antibodies raised against the Yersinia pestis virulence factor LcrV. Biosens Bioelectron 65:47\u201353","journal-title":"Biosens Bioelectron"},{"key":"9_CR99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2016.05.018","volume":"234","author":"R Respaud","year":"2016","unstructured":"Respaud R, Marchand D, Pelat T, Tchou-Wong K-M, Roy CJ, Parent C, Cabrera M, Guillemain J, Mac Loughlin R, Levacher E (2016) Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin. J Control Release 234:21\u201332","journal-title":"J Control Release"},{"key":"9_CR100","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0140-6736(95)91396-3","volume":"346","author":"V Rich","year":"1995","unstructured":"Rich V (1995) Japanese war-time experiments come to light. Lancet 346:566","journal-title":"Lancet"},{"key":"9_CR101","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1128\/CVI.05059-11","volume":"18","author":"V Riddle","year":"2011","unstructured":"Riddle V, Leese P, Blanset D, Adamcio M, Meldorf M, Lowy I (2011) Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Vaccine Immunol 18:2136\u20132142","journal-title":"Clin Vaccine Immunol"},{"key":"9_CR102","volume-title":"Peace or pestilence: biological warfare and how to avoid it","author":"T Rosebury","year":"1949","unstructured":"Rosebury T (1949) Peace or pestilence: biological warfare and how to avoid it. Whittlesey House. McGraw-Hill Co, New York"},{"key":"9_CR103","first-page":"e01501","volume":"7","author":"JW Sahl","year":"2016","unstructured":"Sahl JW, Pearson T, Okinaka R, Schupp JM, Gillece JD, Heaton H, Birdsell D, Hepp C, Fofanov V, Noseda R (2016) A Bacillus anthracis genome sequence from the Sverdlovsk 1979 autopsy specimens. MBio 7:e01501\u2013e01516","journal-title":"MBio"},{"key":"9_CR104","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12199-010-0200-z","volume":"16","author":"H Sato","year":"2011","unstructured":"Sato H (2011) Countermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications. Environ Health Prev Med 16:281\u2013289","journal-title":"Environ Health Prev Med"},{"key":"9_CR105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-8518-2-5","volume":"2","author":"R Sawada-Hirai","year":"2004","unstructured":"Sawada-Hirai R, Jiang I, Wang F, Sun SM, Nedellec R, Ruther P, Alvarez A, Millis D, Morrow PR, Kang AS (2004) Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines 2:5","journal-title":"J Immune Based Ther Vaccines"},{"key":"9_CR106","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/ba711a7c-13fb-4d18-89a8-28dcc68fcd04","volume":"7","author":"DM Schmitt","year":"2012","unstructured":"Schmitt DM, O\u2019Dee DM, Horzempa J, Carlson Jr PE, Russo BC, Bales JM, Brown MJ, Nau GJ (2012) A Francisella tularensis live vaccine strain that improves stimulation of antigen-presenting cells does not enhance vaccine efficacy. PLoS One 7:e31172","journal-title":"PLoS One"},{"key":"9_CR107","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ypmed.2016.09.016","volume":"93","author":"TK Sell","year":"2016","unstructured":"Sell TK, Boddie C, McGinty EE, Pollack K, Smith KC, Burke TA, Rutkow L (2016) News media coverage of US Ebola policies: implications for communication during future infectious disease threats. Prev Med 93:115\u2013120","journal-title":"Prev Med"},{"key":"9_CR108","unstructured":"Services CDoH (2013) SBA\u00a0\u2013 Botulism Immune Globulin Intravenous (Human) (BIG-IV)"},{"key":"9_CR109","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4161\/viru.25454","volume":"4","author":"JA Skyberg","year":"2013","unstructured":"Skyberg JA (2013) Immunotherapy for tularemia. Virulence 4:859\u2013870","journal-title":"Virulence"},{"key":"9_CR110","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1600-065X.2008.00674.x","volume":"225","author":"ST Smiley","year":"2008","unstructured":"Smiley ST (2008) Immune defense against pneumonic plague. Immunol Rev 225:256\u2013271","journal-title":"Immunol Rev"},{"key":"9_CR111","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","volume":"83","author":"GL Smith","year":"2002","unstructured":"Smith GL, Vanderplasschen A, Law M (2002) The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83:2915\u20132931","journal-title":"J Gen Virol"},{"key":"9_CR112","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.micpath.2015.12.013","volume":"92","author":"SJ Southern","year":"2016","unstructured":"Southern SJ, Scott AE, Jenner DC, Ireland PM, Norville IH, Sarkar-Tyson M (2016) Survival protein A is essential for virulence in Yersinia pestis. Microb Pathog 92:50\u201353","journal-title":"Microb Pathog"},{"key":"9_CR113","volume-title":"Weapons of mass casualties and terrorism response handbook","author":"CE Stewart","year":"2006","unstructured":"Stewart CE (2006) Weapons of mass casualties and terrorism response handbook. Jones & Bartlett Learning, Sudbury"},{"key":"9_CR114","doi-asserted-by":"crossref","first-page":"ftw079","DOI":"10.1093\/femspd\/ftw079","volume":"74","author":"E Stinson","year":"2016","unstructured":"Stinson E, Smith LKP, Cole KS, Barry EM, Reed DS (2016) Respiratory and oral vaccination improves protection conferred by the live vaccine strain against pneumonic tularemia in the rabbit model. FEMS Pathogens Dis 74:ftw079","journal-title":"FEMS Pathogens Dis"},{"key":"9_CR115","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1128\/CVI.00003-14","volume":"21","author":"EK Sully","year":"2014","unstructured":"Sully EK, Whaley KJ, Bohorova N, Bohorov O, Goodman C, Kim DH, Pauly MH, Velasco J, Hiatt E, Morton J (2014) Chimeric plantibody passively protects mice against aerosolized ricin challenge. Clin Vaccine Immunol 21:777\u2013782","journal-title":"Clin Vaccine Immunol"},{"key":"9_CR116","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/VDT.S85545","volume":"2016","author":"R Sunagar","year":"2016","unstructured":"Sunagar R, Kumar S, Franz BJ, Gosselin EJ (2016) Tularemia vaccine development: paralysis or progress? Vaccine Dev Ther 2016:9\u201323","journal-title":"Vaccine Dev Ther"},{"key":"9_CR117","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1016\/j.vaccine.2012.05.037","volume":"30","author":"MD Sutherland","year":"2012","unstructured":"Sutherland MD, Goodyear AW, Troyer RM, Chandler JC, Dow SW, Belisle JT (2012) Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia. Vaccine 30:4977\u20134982","journal-title":"Vaccine"},{"key":"9_CR118","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3201\/eid1001.030238","volume":"10","author":"H Takahashi","year":"2004","unstructured":"Takahashi H, Keim P, Kaufmann AF, Keys C, Smith KL, Taniguchi K, Inouye S, Kurata T (2004) Bacillus anthracis bioterrorism incident, Kameido, Tokyo, 1993. Emerg Infect Dis 10:117\u2013120","journal-title":"Emerg Infect Dis"},{"key":"9_CR119","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.bbrc.2016.09.052","volume":"479","author":"S Teimoori","year":"2016","unstructured":"Teimoori S, Seesuay W, Jittavisutthikul S, Chaisri U, Sookrung N, Densumite J, Saelim N, Chulanetra M, Maneewatch S, Chaicumpa W (2016) Human transbodies to VP40 inhibit cellular egress of Ebola virus-like particles. Biochem Biophys Res Commun 479:245\u2013252","journal-title":"Biochem Biophys Res Commun"},{"key":"9_CR120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065855","volume":"8","author":"P Thullier","year":"2013","unstructured":"Thullier P, Avril A, Mathieu J, Behrens CK, Pellequer J-L, Pelat T (2013) Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor. PLoS One 8:e65855","journal-title":"PLoS One"},{"key":"9_CR121","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1016\/S0264-410X(01)00163-3","volume":"19","author":"RW Titball","year":"2001","unstructured":"Titball RW, Williamson ED (2001) Vaccination against bubonic and pneumonic plague. Vaccine 19:4175\u20134184","journal-title":"Vaccine"},{"key":"9_CR122","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1128\/JVI.00406-16","volume":"90","author":"EE Tran","year":"2016","unstructured":"Tran EE, Nelson EA, Bonagiri P, Simmons JA, Shoemaker CJ, Schmaljohn CS, Kobinger GP, Zeitlin L, Subramaniam S, White JM (2016) Mapping of Ebolavirus neutralization by monoclonal antibodies in the ZMapp cocktail using cryo-electron tomography and studies of cellular entry. J Virol 90:7618\u20137627","journal-title":"J Virol"},{"key":"9_CR123","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.mehy.2007.03.012","volume":"69","author":"SI Trevisanato","year":"2007","unstructured":"Trevisanato SI (2007) The \u2018Hittite plague\u2019, an epidemic of tularemia and the first record of biological warfare. Med Hypotheses 69:1371\u20131374","journal-title":"Med Hypotheses"},{"key":"9_CR124","doi-asserted-by":"crossref","first-page":"16554","DOI":"10.1073\/pnas.1008302107","volume":"107","author":"YC Tsai","year":"2010","unstructured":"Tsai YC, Maditz R, Kuo C-L, Fishman PS, Shoemaker CB, Oyler GA, Weissman AM (2010) Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci 107:16554\u201316559","journal-title":"Proc Natl Acad Sci"},{"key":"9_CR125","unstructured":"UNSCOM (1991) UNSCOM: rapport suite \u00e0 la r\u00e9solution 687 du conseil de s\u00e9curit\u00e9 des nations unis du 3 avril 1991"},{"key":"9_CR126","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","volume":"374","author":"J Griensven Van","year":"2016","unstructured":"Van Griensven J, Edwards T, De Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba NF, Antierens A (2016) Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 374:33\u201342","journal-title":"N Engl J Med"},{"key":"9_CR127","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/CVI.00088-16","volume":"23","author":"G Slyke Van","year":"2016","unstructured":"Van Slyke G, Sully EK, Bohorova N, Bohorov O, Kim D, Pauly MH, Whaley KJ, Zeitlin L, Mantis NJ (2016) Humanized monoclonal antibody that passively protects mice against systemic and intranasal ricin toxin challenge. Clin Vaccine Immunol 23:795\u2013799","journal-title":"Clin Vaccine Immunol"},{"key":"9_CR128","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1586\/14760584.2016.1168701","volume":"15","author":"DJ Vance","year":"2016","unstructured":"Vance DJ, Mantis NJ (2016) Progress and challenges associated with the development of ricin toxin subunit vaccines. Expert Rev Vaccines 15:1213\u20131222","journal-title":"Expert Rev Vaccines"},{"key":"9_CR129","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1128\/IAI.00712-06","volume":"74","author":"L Vitale","year":"2006","unstructured":"Vitale L, Blanset D, Lowy I, O\u2019Neill T, Goldstein J, Little SF, Andrews GP, Dorough G, Taylor RK, Keler T (2006) Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun 74:5840\u20135847","journal-title":"Infect Immun"},{"key":"9_CR130","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1128\/CVI.00381-12","volume":"19","author":"ES Vitetta","year":"2012","unstructured":"Vitetta ES, Smallshaw JE, Schindler J (2012) Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine. Clin Vaccine Immunol 19:1697\u20131699","journal-title":"Clin Vaccine Immunol"},{"key":"9_CR131","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/erv.13.37","volume":"12","author":"RP Webb","year":"2013","unstructured":"Webb RP, Smith LA (2013) What next for botulism vaccine development? Expert Rev Vaccines 12:481\u2013492","journal-title":"Expert Rev Vaccines"},{"key":"9_CR132","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000309","volume":"2","author":"TJ Welch","year":"2007","unstructured":"Welch TJ, Fricke WF, McDermott PF, White DG, Rosso M-L, Rasko DA, Mammel MK, Eppinger M, Rosovitz M, Wagner D (2007) Multiple antimicrobial resistance in plague: an emerging public health risk. PLoS One 2:e309","journal-title":"PLoS One"},{"key":"9_CR133","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3201\/eid0809.010536","volume":"8","author":"M Wheelis","year":"2002","unstructured":"Wheelis M (2002) Biological warfare at the 1346 siege of Caffa. Emerg Infect Dis 8:971","journal-title":"Emerg Infect Dis"},{"key":"9_CR134","volume-title":"La guerre bact\u00e9riologique: les secrets des exp\u00e9rimentations japonaises","author":"P Williams","year":"1990","unstructured":"Williams P, Albeck R, Wallace D, Wallace D (1990) La guerre bact\u00e9riologique: les secrets des exp\u00e9rimentations japonaises. A. Michel, Paris"},{"key":"9_CR135","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1099\/jmm.0.037960-0","volume":"61","author":"E Williamson","year":"2012","unstructured":"Williamson E, Oyston P (2012) The natural history and incidence of Yersinia pestis and prospects for vaccination. J Med Microbiol 61:911\u2013918","journal-title":"J Med Microbiol"},{"key":"9_CR136","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1016\/j.vaccine.2011.04.084","volume":"29","author":"E Williamson","year":"2011","unstructured":"Williamson E, Packer P, Waters E, Simpson A, Dyer D, Hartings J, Twenhafel N, Pitt M (2011) Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague. Vaccine 29:4771\u20134777","journal-title":"Vaccine"},{"key":"9_CR137","volume":"5","author":"X Xiao","year":"2010","unstructured":"Xiao X, Zhu Z, Dankmeyer JL, Wormald MM, Fast RL, Worsham PL, Cote CK, Amemiya K, Dimitrov DS (2010) Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model. PLoS One 5:e13047","journal-title":"PLoS One"},{"key":"9_CR138","doi-asserted-by":"crossref","first-page":"22721","DOI":"10.1038\/srep22721","volume":"6","author":"A Yermakova","year":"2016","unstructured":"Yermakova A, Klokk TI, O\u2019Hara JM, Cole R, Sandvig K, Mantis NJ (2016) Neutralizing monoclonal antibodies against disparate epitopes on ricin toxin\u2019s enzymatic subunit interfere with intracellular toxin transport. Sci Rep 6:22721","journal-title":"Sci Rep"},{"key":"9_CR139","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/jama.1997.03550050080037","volume":"278","author":"RA Zilinskas","year":"1997","unstructured":"Zilinskas RA (1997) Iraq\u2019s biological weapons: the past as future? JAMA 278:418\u2013424","journal-title":"JAMA"}],"container-title":["Advances in Experimental Medicine and Biology","Recombinant Antibodies for Infectious Diseases"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-72077-7_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T13:58:04Z","timestamp":1720274284000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-72077-7_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319720760","9783319720777"],"references-count":139,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-72077-7_9","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}